The retrospective cohort study, led by Reweiguli Aihaiti and colleagues at Ruijin Hospital, affiliated with the Shanghai Jiao Tong University School of Medicine, drew on 3,285 patients who underwent frozen embryo transfer at the hospital’s Reproductive Medical Center between January 2015 and December 2022. After applying strict exclusion criteria, the team analyzed 2,543 women who delivered singleton live births and had complete pre-pregnancy menstrual cycle data. Participants were divided into four groups according to cycle length: 27 days or fewer, 28 to 31 days, 32 to 35 days, and 36 days or more. The reference category, encompassing roughly 71 percent of the cohort, was the conventional 28-to-31-day cycle, long considered the physiological gold standard.

The statistical architecture of the study was deliberately conservative. The investigators used multivariable logistic regression to estimate adjusted odds ratios for gestational diabetes and gestational hypertension, controlling for an unusually broad set of potential confounders: maternal age, body mass index, parity, causes and duration of infertility, fertilization method, ovarian stimulation protocol, number of transferable embryos, endometrial preparation method, embryo stage, and the number of embryos transferred. Patients with comorbidities known to disrupt both menstruation and pregnancy outcomes were excluded outright, and none of the participants had used oral contraceptives in the three months preceding their transfer, removing another potential source of distortion.

The results were striking in their consistency. Women with prolonged cycles of 36 days or longer had a 54 percent higher adjusted odds of developing gestational diabetes compared with women in the reference group, with an adjusted odds ratio of 1.54 and a 95 percent confidence interval of 1.14 to 2.09. Their adjusted odds of gestational hypertension were 60 percent higher, at 1.60. Perhaps more unexpectedly, cycles of 32 to 35 days, only modestly longer than normal, were also associated with a 59 percent increase in the odds of gestational hypertension. The raw incidence rates told the same story: gestational diabetes affected 25.6 percent of women with prolonged cycles, and gestational hypertension reached 12.2 percent in that group, both the highest figures across the four cycle-length categories.

Shorter cycles told the opposite story. Women whose cycles ran 27 days or fewer had roughly half the adjusted odds of developing gestational diabetes, with an adjusted odds ratio of 0.49, compared with the reference group. This protective association, the authors note, had been hinted at in earlier population-based research but had never been demonstrated in an IVF population free of polycystic ovary syndrome. The dose-response-like gradient, in which risk rises as cycle length lengthens and falls as it shortens, strengthens the biological plausibility of the association and argues against a statistical fluke.

What could a longer menstrual cycle possibly have to do with the way a placenta handles glucose or a maternal vasculature tolerates the hemodynamic load of pregnancy? The authors point to a chain of endocrine mechanisms documented in prior literature. Prolonged cycles are associated with hyperinsulinemia, and chronically elevated insulin suppresses hepatic production of sex hormone-binding globulin, which in turn raises levels of free circulating testosterone. Both insulin resistance and androgen excess are established risk factors for gestational diabetes. Longer cycles have also been linked to abnormalities in lipid metabolism and broader metabolic disturbance, conditions that independently predispose women to impaired glucose tolerance during pregnancy.

The connection to gestational hypertension may run through related but distinct physiology. Gestational glucose intolerance has previously been tied to hypertensive disorders of pregnancy, independent of obesity and blood glucose levels, in part because insulin resistance drives both inflammatory dysregulation and vascular dysfunction. The new study adds a novel piece of evidence by linking prolonged menstrual cycles, a marker of long-term endocrine milieu, to hypertension risk specifically in the absence of polycystic ovary syndrome. The finding dovetails with large epidemiological studies showing that women with long or irregular cycles face elevated lifetime risks of cardiovascular disease, ischemic heart disease, heart failure, hypertension, and type 2 diabetes. In a nationwide UK cohort of more than 700,000 women, cycle irregularity predicted a cluster of cardiometabolic outcomes years later.

The clinical implications are immediate for the fertility field. Frozen embryo transfer is performed under tightly controlled hormonal conditions, with endometrial preparation through natural cycles or hormone replacement protocols and progesterone support timed to precise endometrial thresholds. Yet even within this engineered environment, the underlying metabolic predisposition of the patient appears to assert itself. The authors argue that menstrual cycle length should be treated as a risk factor warranting screening before IVF treatment begins, and that combining cycle characteristics with body mass index in routine pre-treatment evaluations could identify women who would benefit from early glucose monitoring, blood pressure surveillance, and preventive intervention during pregnancy.

The study is not without limitations, and the authors are candid about them. The retrospective design precluded measurement of baseline insulin and lipid profiles, so the proposed mechanisms remain inferential rather than directly demonstrated. The cohort was restricted to frozen embryo transfer cycles, leaving open the question of whether the same associations hold for fresh transfers, where supraphysiological estradiol levels add their own metabolic noise. Supplementary analyses stratifying the population more finely showed that women with extraordinarily long cycles of 60 days or more had numerically elevated risks of both complications, with adjusted odds ratios of 2.06 for gestational diabetes and 1.88 for gestational hypertension, but the sample in that subgroup was too small for the results to reach statistical significance.

Even so, the study represents a first. No previous investigation had examined the relationship between menstrual cycle length and pregnancy complications in women without polycystic ovary syndrome undergoing IVF with frozen embryo transfer, a population that continues to grow as freeze-all strategies become standard practice in clinics worldwide. The message for patients is not alarm but attention: a menstrual cycle that reliably stretches beyond five weeks is not merely a fertility inconvenience or an aesthetic quirk of biology. It may be a visible readout of an invisible metabolic state, one that shapes pregnancy outcomes and, according to a growing body of evidence, long-term cardiovascular health. Larger prospective studies will be needed to confirm the findings and to test whether early intervention, from lifestyle modification to pharmacologic glucose management, can convert this new risk marker into a preventable outcome.

Subject of Research: The association between pre-pregnancy menstrual cycle length and the risk of gestational diabetes mellitus and gestational hypertension in women without PCOS undergoing frozen embryo transfer.

Article Title: Associations of menstrual cycle length with GDM and gestational hypertension in frozen embryo transfer

Article References: Aihaiti, R., Zhu, Z., Wu, X., Shen, Z., & Niu, Z. (2026). Associations of menstrual cycle length with GDM and gestational hypertension in frozen embryo transfer. Journal of Ovarian Research, 19(1), Article 277. https://doi.org/10.1186/s13048-026-02168-w

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02168-w

Keywords: menstrual cycle length, gestational diabetes mellitus, gestational hypertension, frozen embryo transfer, in vitro fertilization, polycystic ovary syndrome, insulin resistance, pregnancy complications, reproductive medicine, cardiometabolic risk, IVF outcomes, retrospective cohort study